• Devonian Health Group posted a net loss of CAD 1.9 million, or CAD 0.70 per share, for the quarter ended April 30, 2026.
• The loss narrowed from CAD 4.8 million a year earlier, when results included a CAD 4.8 million impairment tied to the Altius generic business.
• For the nine months ended April 30, 2026, net loss was CAD 5.7 million, or CAD 2.07 per share.
• Cash totaled CAD 0.7 million at April 30, 2026; the company said it remains debt-free.
• Devonian kept focus on Thykamine in radiodermatitis prevention and pediatric atopic dermatitis, while evaluating MASH and fibrotic-disease potential.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Devonian Health Group Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606292000PR_NEWS_USPR_____MO94918) on June 30, 2026, and is solely responsible for the information contained therein.